Application of PAX1 Methylation Combined with HR-HPV Typing Detection in Cervical Diseases

Objective: To investigate the clinical value of PAX1 methylation quantitative detection in cervical diseases. By comparing the correlation between PAX1 methylation, HR-HPV, TCT and clinicopathological results, it provides a theoretical basis for early diagnosis and screening of cervical cancer. Methods: A total of 108 patients from June 2016 to May 2018 in the Department of Cervical Medicine of Xuzhou Maternity and Child Health Care Hospital were selected. The pathological results were used as the diagnostic criteria. The patients were divided into four groups: 22 cases in chronic cervicitis group, 30 cases in LSIL group, 31 cases in HSIL group and 25 cases in cervical cancer group. Cervical exfoliated cells were collected from all patients. The status and level of methylation of PAX1 were detected by methylation fluorescence quantitative PCR, and HR-HPV typing and TCT were detected simultaneously. If any of the three indicators was positive, colposcopic biopsy was conducted, and then the test results were analyzed statistically to compare the sensitivity, specificity, diagnostic coincidence rate of single or combined screening program in the three screening methods. Results: The methylation level of PAX1 in cervical cancer group was significantly higher than that in other groups, and the difference among the groups was statistically significant (P<0.001). The sensitivity, specificity and diagnostic coincidence rate of PAX1 methylation detection in high-grade cervical lesions and above lesions were 76.79%, 90.38%, and 83.33%, respectively; the sensitivity, specificity and diagnostic coincidence rate of high-risk HPV typing detection in high-grade cervical lesions and above lesions were 87.50%, 75.00%, and 81.48%, respectively; the sensitivity, specificity, and diagnostic coincidence rate of TCT detection in high-grade cervical lesions and above lesions were 58.93%, 73.08%, and 65.74%, respectively. Screening alone: the sensitivity of HPV was the highest and the specificity of PAX1 was the highest. The combined screening: the sensitivity of PAX1 + HPV was the highest (94.64%), and the specificity was 75.00%, and the diagnostic coincidence rate was 85.19%.Conclusion: The PAX1 methylation detection has high specificity in high-grade cervical lesions and above lesions, especially PAX1 combined with HR-HPV detection has high clinical value for screening of high-grade cervical lesions and above lesions, which can be used as the clinical new way of cervical cancer screening.